Conflict of interest: None.
Expert recommendations on the application of interferon for chronic hepatitis B
Article first published online: 5 NOV 2013
© 2013 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd
Journal of Digestive Diseases
Volume 14, Issue 12, pages 626–637, December 2013
How to Cite
Wan, M. B. and Weng, X. H. (2013), Expert recommendations on the application of interferon for chronic hepatitis B. Journal of Digestive Diseases, 14: 626–637. doi: 10.1111/1751-2980.12096
The study has been published in Chinese in Chin J Infect Dis 2010; 28: 193–200 (‘Expert recommendations on the treatment of chronic hepatitis B with interferon [revision 2010]’) and Chin J Infect Dis 2012; 30: 705–10 (‘Some additions to the expert recommendations on the treatment of chronic hepatitis B with interferon’), with modifications.
- Issue published online: 5 NOV 2013
- Article first published online: 5 NOV 2013
- Accepted manuscript online: 23 AUG 2013 07:43AM EST
- expert recommendation;
- response-guided therapy;
- chronic hepatitis B;
- optimized therapy
To help the clinicians correctly and scientifically apply interferon for the treatment of chronic hepatitis B, more than 40 experts majored in infectious and liver diseases updated the ‘Expert recommendations on the treatment of chronic hepatitis B with interferon (2007)’ following a systematic literature review, summary of clinical experiences and thorough consultation and discussion. The updated expert recommendations primarily included fundamental new knowledge of the use of interferon and individualized interferon therapy. Specifically, we provided recommendations for implementing optimized therapeutic regimens based on quantitative changes in hepatitis B surface antigen and hepatitis B virus DNA levels 24 weeks after interferon therapy. The updated expert recommendations provided itemized details and supplement for the Guidelines for the Prevention and Treatment of Chronic Hepatitis B and they also offer a basis for individualized therapy of chronic hepatitis B with interferon.